InvestorsHub Logo
Followers 3
Posts 1277
Boards Moderated 1
Alias Born 04/02/2003

Re: None

Thursday, 09/27/2007 1:00:09 PM

Thursday, September 27, 2007 1:00:09 PM

Post# of 26



Celsion Bolsters Clinical Development Team
Thursday September 27, 9:43 am ET


COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (AMEX: CLN - News) today announced the appointment, effective October 1, 2007, of Nicholas Borys, M.D. to the position of Vice President and Chief Medical Officer. In this position Dr. Borys will manage the clinical development program for Celsion.
ADVERTISEMENT


Dr. Borys, who was most recently Chief Medical Officer at Molecular Insight Pharmaceuticals, Inc., has accumulated extensive experience in oncology and all phases of pharmaceutical development while holding increasingly senior positions at Taiho Pharma USA, Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc.

Dr. William Hahne, Celsion's Vice President, Clinical and Medical Affairs will collaborate with Dr. Borys on developing Celsion's clinical strategy for its current primary liver cancer and recurrent breast cancer at the chest wall pivotal programs. In addition, they will explore and identify additional indications for ThermoDox®, the company's proprietary heat activated liposomal formulation of doxorubicin, as well as other chemotherapeutic drugs, based on the company's unique heat activated liposome platform technology.

Michael H. Tardugno, Celsion's President and Chief Executive Officer commented, "We are delighted that Dr. Borys has joined our team. Dr. Borys has a wealth of clinical development experience with a strong focus on oncology, and will be very valuable to the company as it initiates its primary liver cancer pivotal study, and develops plans to advance the recurrent breast cancer at the chest wall program to a pivotal study."

Mr. Tardugno added, "Dr. Borys' addition is in line with our focus of building an organization with the clinical and scientific competencies to execute our strategy. Both Dr. Hahne and Dr. Borys have extensive experience in the oncology arena. The product of their collective strength and experience should prove to be a very valuable asset for Celsion."